Ophthalmic Composition for Reduced Intraocular Pressure Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for elevated intraocular pressure associated with glaucoma, such as those involving brinzolamide and brimonidine, face challenges including significant side effects and complex administration regimens, with a need for more effective and tolerable options that reduce dosing frequency while maintaining efficacy.
Innovation Solution
Development of ophthalmic compositions comprising brinzolamide and brimonidine, with a borate-polyol complex and a penetration enhancer, allowing for once or twice daily administration, which demonstrates bioequivalence or improved pharmacokinetic properties compared to standard three-times-daily regimens, reducing adverse events and enhancing patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If brimonidine and brinzolamide are administered three times daily as standard regimen, then intraocular pressure control is achieved, but patient compliance deteriorates and adverse events increase
Solution Approach 1:
The patent combines brimonidine and brinzolamide into a single fixed-dose combination ophthalmic solution, allowing both medications to be administered together in one drop rather than requiring separate administrations. This merging of two drugs into one formulation directly reduces dosing frequency and improves patient compliance while maintaining the therapeutic effectiveness of both agents for intraocular pressure control
Solution Approach 2:
The patent utilizes a penetration enhancer component that modifies the physical-chemical parameters of the ophthalmic solution to improve drug penetration and bioavailability. This parameter change allows for reduced dosing frequency (once or twice daily instead of three times daily) while maintaining effective intraocular pressure control, thereby improving patient compliance without sacrificing therapeutic reliability
2Reliability
If brimonidine is administered to reduce intraocular pressure, then efficacy is improved, but side effects increase
Solution Approach 1:
The patent introduces a penetration enhancer as an intermediary component that facilitates improved drug delivery and bioavailability. This intermediary substance allows for reduced dosing frequency and potentially lower total drug exposure while maintaining efficacy, thereby reducing the occurrence of side effects such as ocular hyperemia, burning, stinging, and systemic effects like sedation and dry mouth that are associated with standard brimonidine therapy
3Reliability
If multidrug regimens are used to treat elevated intraocular pressure, then treatment efficacy is improved, but administration complexity increases
Solution Approach 1:
The patent merges brimonidine and brinzolamide into a single fixed-dose combination formulation, eliminating the need for separate administrations of each drug. This single solution contains both active ingredients at optimized concentrations, allowing patients to administer one drop instead of multiple drops or separate medications, thereby maintaining the additive therapeutic efficacy of both drugs while dramatically simplifying the administration regimen
Solution Approach 2:
The ophthalmic solution serves multiple functions simultaneously: it contains both brimonidine (alpha-2-adrenergic agonist) and brinzolamide (carbonic anhydrase inhibitor) in optimized concentrations, includes a penetration enhancer for improved bioavailability, and provides preservative protection. This multi-functional formulation consolidates what would otherwise require multiple separate products into a single universal solution, reducing administration complexity while maintaining comprehensive treatment efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide effective intraocular pressure control with reduced dosing frequency, improved tolerability, and enhanced bioavailability, addressing the limitations of existing treatments by offering a more convenient and effective regimen for glaucoma management.
Implementation Method 1
compositions comprising a combination of brinzolamide and brimonidine, compositions comprising borate-polyol complexes
Implementation Method 2
compositions comprising use of two different polyols... and a penetration enhancer
Data Source
AI summary
Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products.